Home › Funds › Lombard Odier Asset Management (Europe) Ltd › HALO

Lombard Odier Asset Management (Europe) Ltd position in HALO

HALOZYME THERAPEUTICS INC · Health Care

Lombard Odier Asset Management (Europe) Ltd reported holding 19,789,000 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$29.1M, representing 1.54% of its reported portfolio and ranking #8 among its reported holdings. Lombard Odier Asset Management (Europe) Ltd has disclosed HALO holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)19.79M sh
Reported value held$29.09M
Portfolio Weight1.54%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Lombard Odier Asset Management (Europe) Ltd's HALO position evolved

Lombard Odier Asset Management (Europe) Ltd first disclosed a stake in HALO in Q3 2023 at 1,778,000 shares (US$1.5M). The position peaked in Q2 2026 at 19,789,000 shares, worth US$29.1M. Across 11 filings, Lombard Odier Asset Management (Europe) Ltd increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 19,789,000 shares valued at US$29.1M — a reduction of -180,000 shares quarter over quarter.. Notable position changes include a 93% trim in Q3 2024 (shares fell 16% over the following quarter), a 31% increase in Q4 2024 (shares rose 33% over the following quarter), a 1634% increase in Q2 2025 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.78M $1.51M New
Q4 2023 1.78M $1.54M Hold
Q1 2024 1.78M $1.58M Hold
Q2 2024 1.78M $1.69M Hold
Q3 2024 125.00K $7.16M Reduce
Q4 2024 163.67K $7.83M Add
Q1 2025 144.14K $9.20M Reduce
Q2 2025 2.50M $2.49M Add
Q4 2025 15.49M $20.58M New
Q1 2026 19.97M $25.74M Add
Q2 2026 19.79M $29.09M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 43 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$196.5M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has Lombard Odier Asset Management (Europe) Ltd held HALO?

Lombard Odier Asset Management (Europe) Ltd has disclosed HALO holdings in 11 of the last 12 reported quarters, going back to Q3 2023.

What is Lombard Odier Asset Management (Europe) Ltd's current position in HALO?

As of Q2 2026, Lombard Odier Asset Management (Europe) Ltd holds 19.79M shares of HALO (HALOZYME THERAPEUTICS INC), valued at $29.09M, representing 1.54% of its reported portfolio and ranking #8.

Has Lombard Odier Asset Management (Europe) Ltd been buying or selling HALO?

In the latest 13F filing (Q2 2026), Lombard Odier Asset Management (Europe) Ltd reduced its position in HALO. The position peaked in Q2 2026 at 19.79M shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, SNYDER CAPITAL MANAGEMENT L P, among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.